Parthenon Research
Long/short equity, growth at reasonable price, special situations, value

Aegerion And The Orphan Drug Paradox

Once Scorned, Orphan Diseases Have Become Popular

Companies developing drugs for Orphan Disease have emerged as a specialty group within the Biotechnology industry. These companies are using provisions of the 1984 Orphan Drug Legislation that provide FDA assistance, financial and tax incentives, and favorable reimbursement. During the first 15 years after the legislation, Orphan Drug approvals increased attention to rare diseases and led to a few successful product introductions. There have been some outstanding successes, leading more companies to focus on orphan drugs. However, we believe this overlooks the difficulties involved in rare diseases.

The business model for an Orphan Drug company was largely pioneered by Genzyme in 1990s, which demonstrated that rare diseases could lead to profitable products. At...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details